However, there are several ongoing TGF-β directed clinical trials conducted on patients with fibrotic diseases of other organs than the liver that, if successful, could be transferred to liver diseases and tested in well-controlled clinical trials. The gene discussed is TGFB1; the disease is liver disorder.